Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Demonstrates Long-Term Growth Potential At 9.4% CAGR

The field of nucleic acid and gene therapies targeting neuromuscular disorders is poised for impressive expansion in the coming years. With rapid scientific progress and increased investment, this specialized market is attracting significant attention due to its potential to transform treatment options and improve patient outcomes. Let's explore the current market size, key industry players, emerging trends, and the major segments propelling this growth.

Projected Market Growth and Size of the Nucleic Acid and Gene Therapies in Neuromuscular Disorders
The market for nucleic acid and gene therapies focused on neuromuscular disorders is anticipated to grow substantially, reaching a value of $11.76 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 9.4% over the forecast period. Several factors contribute to this robust growth, including advancements in adeno-associated virus (AAV) technology and postnatal gene therapies, increasing research and development expenditure in neuromuscular disorders (NMDs), and a greater number of hospitals and specialty clinics offering these cutting-edge therapies. Additionally, the rising prevalence of neuromuscular conditions, along with enhanced patient awareness and advocacy efforts, plays a significant role. Key trends expected to drive the market forward include wider adoption of gene therapy techniques, intensified development of nucleic acid-based therapeutics, a growing focus on rare neuromuscular diseases, increased investment in personalized medicine, and the integration of sophisticated diagnostic and monitoring technologies.

The nucleic acid and gene therapies in neuromuscular disorders market size has grown strongly in recent years. It will grow from $7.5 billion in 2025 to $8.22 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to limited therapeutic options for nmds, low awareness of gene therapies, high cost of gene therapy development, lack of specialized treatment centers, slow regulatory approvals.

Download a free sample of the nucleic acid and gene therapies in neuromuscular disorders market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Important Factors Propelling Market Expansion in the Nucleic Acid and Gene Therapies Sector
The rising number of neuromuscular disorder cases worldwide is a primary factor pushing market growth. This increase has prompted significant research investments aimed at developing effective gene-based treatments to address these complex conditions.
Simultaneously, a surge in patient advocacy and awareness campaigns is encouraging earlier diagnosis and treatment uptake, which further fuels demand for innovative therapies. The expansion of specialized healthcare facilities offering gene and nucleic acid therapies also supports improved accessibility for patients.

Prominent Industry Players in the Nucleic Acid and Gene Therapies for Neuromuscular Disorders Market
The competitive landscape includes several leading pharmaceutical and biotechnology companies such as Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, and Regenxbio Inc. Additional key participants are UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, and Takeda Pharmaceutical Company Ltd.
A notable industry event occurred in November 2024 when Novartis AG acquired Kate Therapeutics Inc. for $1.1 billion. This acquisition aims to strengthen Novartis's gene therapy portfolio for inherited neuromuscular disorders by incorporating Kate Therapeutics' AAV-based DELIVER gene therapy platform, along with preclinical candidates targeting Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and myotonic dystrophy type 1. Kate Therapeutics, headquartered in the United States, specializes in AAV gene therapies for muscle and heart diseases defined by genetic causes.

View the full nucleic acid and gene therapies in neuromuscular disorders market report:
https://www.thebusinessresearchcompany.com/report/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Innovative Trends Shaping the Nucleic Acid and Gene Therapies Market
Companies within this market are actively developing gene therapy approaches designed to tackle the underlying genetic defects of neuromuscular disorders. Gene therapy involves introducing, modifying, or repairing genetic material inside patient cells to correct faulty genes or replace missing ones.
An example of this innovation is the approval of Elevidys by Sarepta Therapeutics Inc. in June 2023. Elevidys is the first gene therapy authorized by the U.S. Food and Drug Administration for treating Duchenne Muscular Dystrophy in ambulatory pediatric patients aged 4 to 5 years. Delivered as a single intravenous infusion, this treatment simplifies administration compared to therapies requiring multiple doses. Elevidys supplies a gene coding for micro-dystrophin, a shorter version of the dystrophin protein vital for muscle function, potentially halting or reversing disease progression by enabling muscle cells to produce a functional protein.

Examining Core Segments Driving Market Growth in Nucleic Acid and Gene Therapies for Neuromuscular Disorders
This market is categorized by disorder type, therapy type, and end-user, providing a detailed framework for understanding growth drivers.
Disorder categories include Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, and Myopathies-including muscular dystrophies.
Therapy types primarily consist of Adeno-Associated Virus gene therapy and postnatal gene therapy.
End-users comprise hospitals, specialty clinics, and ambulatory surgery centers.
Further subsegments break down disorders more specifically: Motor Neuron Diseases include Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and Primary Lateral Sclerosis (PLS); Neuropathies cover Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), and peripheral neuropathies; Neuromuscular Junction Disorders include Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome (LEMS); and Myopathies cover Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), and Facioscapulohumeral Muscular Dystrophy (FSHD).

What's new in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.